Gensight Biologics SA
PAR:SIGHT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (19.9), the stock would be worth €-0.6 (835% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2.7 | €0.08 |
0%
|
| Industry Average | 19.9 | €-0.6 |
-835%
|
| Country Average | 15.8 | €-0.48 |
-684%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
|
Gensight Biologics SA
PAR:SIGHT
|
18m EUR | -2.7 | -1.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 184.9 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 22.9 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 28 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 18.4 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 31.7 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.1 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 15.3 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 141.8 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -64.3 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 21.3 | 30.7 |
Market Distribution
| Min | 0.9 |
| 30th Percentile | 10.4 |
| Median | 15.8 |
| 70th Percentile | 25.1 |
| Max | 2 752.4 |
Other Multiples
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
